Biodesix test predicts response to atezolizumab in lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq) in patients with non-small cell lung cancer.

The blood-based test, which uses expression data from the circulating proteome to classify patients, was found to be predictive for OS and PFS between atezolizumab and docetaxel, the companies said.

Genentech is a member of the Roche Group.

These data suggest a patient’s likelihood of benefiting from PD-L1 checkpoint inhibition can be identified through circulating proteome in blood samples. Researchers presented their findings at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C.

Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login